Viral and Non-Viral Vector Manufacturing Global Market Report 2024

The viral and non-viral vector manufacturing market size has grown rapidly in recent years. It will grow from $7.22 billion in 2023 to $8.62 billion in 2024 at a compound annual growth rate (CAGR) of 19.5%. The expansion in the historic period can be attributed to the rising prevalence of genetic disorders, advancements in biotechnology, increasing investments in gene therapy research, growing awareness of personalized medicine, and regulatory support for gene therapy development.

The viral and non-viral vector manufacturing market size is expected to see rapid growth in the next few years. It will grow to $17.85 billion in 2028 at a compound annual growth rate (CAGR) of 20.0%. The anticipated increase during the forecast period can be ascribed to the increasing need for gene therapies, the broader utilization of treatments for rare diseases, heightened investments in biomanufacturing infrastructure, and the growing acceptance of precision medicine. Notable trends expected in the forecast period encompass the progression of next-generation viral vectors, a heightened utilization of CRISPR/Cas9 technology in vector manufacturing, an emphasis on scalable and cost-efficient manufacturing processes, a rising adoption of non-viral vectors, and advancements in technologies for manufacturing cell and gene therapies.

The growth of the viral and non-viral vector manufacturing markets is anticipated to be fueled by the increasing prevalence of genetic disorders. Genetic disorders arise from deviations in the typical DNA sequence, and viral vectors play a crucial role in delivering therapeutic genes to target cells, addressing defective genes causing these disorders. Non-viral vectors are commonly employed in ex vivo gene therapy, modifying cells outside the body before reintroducing them into the patient. For example, as reported by Versus Arthritis in June 2023, the number of people with rheumatoid arthritis, psoriatic arthritis, and osteoarthritis is expected to rise, highlighting the escalating incidence of genetic disorders and thereby propelling the growth of viral and non-viral vector manufacturing markets.

The growth of the viral and non-viral vector manufacturing markets is expected to be driven by the increasing number of clinical trials. Clinical trials, essential for evaluating the safety and efficacy of medical interventions, rely on viral and non-viral vectors to deliver therapeutic genes and ensure vector quality throughout trial phases. According to data from ClinicalTrials.gov in December 2023, the number of registered clinical trials has risen, with an increase in both registration and completion figures, underlining the pivotal role of these vectors in supporting gene therapy clinical trials and contributing to market growth.

A prominent trend in the viral and non-viral vector manufacturing markets is technological advancements. Key companies are investing in advanced solutions to maintain their market position. For instance, in August 2022, Merck KGaA launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, providing a comprehensive viral vector manufacturing package. This innovative platform enables biopharmaceutical companies to streamline process development, reducing time and costs associated with clinical manufacture, showcasing the significance of technological advancements in driving market growth.

Major companies in the viral and non-viral vector manufacturing market are actively pursuing partnerships to enhance profitability. Collaborative efforts involve biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), research institutions, and technology providers working together to improve efficiency, safety, and scalability of non-viral vector development and production. For instance, in September 2023, NecstGen and ProteoNic BioSciences collaborated to launch ProteoNic's 2G UNic premium vector technology, contributing to improved lentiviral (LV) vector development and production efficiency, ultimately benefiting gene therapies and non-vector processes.

In January 2021, Thermo Fisher Scientific Inc. acquired Henogen S.A. for $874.5 million, aiming to enhance its global capacity for cell and gene therapies and vaccines. Henogen S.A., a biomanufacturing company based in Belgium, provides bioprocess development and viral vector manufacturing services, exemplifying the strategic moves within the industry to expand capabilities and meet growing demands.

Major companies operating in the viral and non-viral vector manufacturing market report are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.

North America was the largest region in the viral and non-viral vector manufacturing market in 2023. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral and non-viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The main types of viral and non-viral vectors in manufacturing are viral vectors and non-viral vectors. Viral vectors are commonly used in gene therapy and gene editing to introduce therapeutic genes or alter the expression of existing genes in living organisms. These vectors are applied in the treatment of various diseases, including cancer, genetic diseases, infectious diseases, cardiovascular diseases, and others. They play a crucial role in gene therapy, vaccinology, cell therapy, and other related fields.

The viral and non-viral vector manufacturing vectors market research report is one of a series of new reports that provides viral and non-viral vector manufacturing vectors market statistics, including viral and non-viral vector manufacturing vectors industry global market size, regional shares, competitors with a viral and non-viral vector manufacturing vectors market share, detailed viral and non-viral vector manufacturing vectors market segments, market trends and opportunities, and any further data you may need to thrive in the viral and non-viral vector manufacturing vectors industry. This viral and non-viral vector manufacturing vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral and non-viral vector manufacturing market includes revenues earned by entities by providing adeno-associated viral vectors, lentiviral vectors, retroviral vectors, adenoviral vectors, particle-based vectors, and chemical-based vectors. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.